Wave shares results from repeat dosing of RNA editing therapy for AATDnews2025-09-03T11:30:31+00:00September 3rd, 2025|Endpoints News|
How past Endpoints 11 winners fared during 2025’s biotech downturnnews2025-09-03T11:00:44+00:00September 3rd, 2025|Endpoints News|
Post-Hoc Live: How we chose this year’s best biotech startups, and how past picks have farednews2025-09-03T11:00:11+00:00September 3rd, 2025|Endpoints News|
Exclusive: Mytos inks cell therapy manufacturing deals with three European biotechs news2025-09-03T07:00:17+00:00September 3rd, 2025|Endpoints News|
Prasad spells out new thinking on vaccine development in Covid-19 memosnews2025-09-02T19:28:50+00:00September 2nd, 2025|Endpoints News|
United’s lung disease drug Tyvaso succeeds in Phase 3 IPF trialnews2025-09-02T18:45:33+00:00September 2nd, 2025|Endpoints News|
RFK Jr. critic Paul Offit dismissed from FDA’s vaccine advisory committeenews2025-09-02T17:41:58+00:00September 2nd, 2025|Endpoints News|
Merck claims another late-stage win for oral cholesterol drugnews2025-09-02T16:41:53+00:00September 2nd, 2025|Endpoints News|
Amgen to expand California headquarters with new $600M R&D center news2025-09-02T16:19:01+00:00September 2nd, 2025|Endpoints News|
Vertex enlists Enlaza for gene therapy conditioning and autoimmune disease pactnews2025-09-02T15:34:54+00:00September 2nd, 2025|Endpoints News|
